Safety Reading Notes

Read safety context beside the research guide.

The Glycine receptors source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 33522084

PubMed For Dummies Article

Glycine receptors Evidence Review: the long-form source walk-through

Quick read
  • Glycine receptors currently has 15 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33522084
  • The evidence classes most visible in the row language are insufficient (8), mechanistic or pharmacological (6), and preclinical (1). PMID 23924692
  • The study-design language most visible in the row language is Narrative or expert review (6), Animal study (5), Cellular or in vitro study (3), and other mapped categories (1). PMID 39657242
  • The repeated topics are receptor, target, or pharmacology mechanisms (15), which tells the reader where to start opening PubMed and DOI links. PMID 42212209

Start with the research question

Glycine receptors is built from 15 source-backed evidence row(s) and 15 research source(s). The current evidence classes read as insufficient (8), mechanistic or pharmacological (6), and preclinical (1), and the study-design language most often reads as Narrative or expert review (6), Animal study (5), Cellular or in vitro study (3), and other mapped categories (1). PMID 33522084

The row-level question is not simply whether Glycine receptors is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, or pharmacology mechanisms (15). PMID 21557733

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 40432283

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 36439263

Mechanistic evidence 6 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 21557733

Limits and uncertainty 8 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 18755158

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 22585736

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, or pharmacology mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, target, or pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 33522084

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 21557733

Bucket chapters: what the literature is circling

receptor, target, or pharmacology mechanisms

6 research sources 6 rows (253-261) Mechanistic and preclinical research summary: insufficient (3), mechanistic or pharmacological (2), preclinical (1)

Glycine receptors appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33522084

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 33522084

  • Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

  • Evidence row 261

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (259-267) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

Glycine receptors appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 5 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21557733

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21557733

  • Evidence row 259

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 21557733

  • Evidence row 267

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome m... PMID 11347816

receptor, target, or pharmacology mechanisms

4 research sources 4 rows (258-265) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)

Glycine receptors appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 4 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 36439263

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36439263

  • Evidence row 258

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263

  • Evidence row 265

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: re... PMID 28861502

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (6 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33522084

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 21557733

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 16107637
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 35091505
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 15589342

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33522084

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 21557733

Source-reading checklist for Glycine receptors

  1. Open the linked PubMed or DOI record. PMID 28861502
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 33631255
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 11347816
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 33522084
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 23924692

Source Notes

Glycine receptors source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

    Evidence class: insufficient; Study design: Animal study. Source: Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
  2. Evidence row 254

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 23924692

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
  3. Evidence row 255

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39657242

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.
  4. Evidence row 256

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
  5. Evidence row 257

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40432283

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets.
  6. Evidence row 258

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263

    Evidence class: insufficient; Study design: Systematic review. Source: Cys-loop receptors on cannabinoids: All high?
  7. Evidence row 259

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 21557733

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric modulation of glycine receptors.
  8. Evidence row 260

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 18755158

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.
  9. Evidence row 261

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736

    Evidence class: preclinical; Study design: Animal study. Source: Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
  10. Evidence row 262

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 16107637

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.
  11. Evidence row 263

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35091505

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents.
  12. Evidence row 264

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 15589342

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse.
  13. Evidence row 265

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 28861502

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Parkinson's Disease.
  14. Evidence row 266

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33631255

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Tolerance to alcohol: A critical yet understudied factor in alcohol addiction.
  15. Evidence row 267

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 11347816

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release.